03:43 AM EDT, 04/01/2025 (MT Newswires) -- Pfizer ( PFE ) said Tuesday the European Commission approved its Abrysvo vaccine for the prevention of lower respiratory tract disease caused by respiratory syncytial virus, or RSV, in individuals aged 18 to 59.

The Commission granted marketing authorization for the vaccine, which was first approved for adults aged 60 years and older.

The approval is based on a phase 3 clinical trial, which evaluated the safety, tolerability and immunogenicity of the vaccine in patients at risk of RSV-associated lower respiratory tract disease, according to Pfizer ( PFE ).